Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever

Basit Öğe Kaydı
dc.authoridIlgen, Ufuk/0000-0001-6443-6426
dc.authoridTURGAY, TAHSIN MURAT/0000-0001-5302-4485
dc.authoridAtes, Askin/0000-0003-1966-3333
dc.contributor.authorKucuksahin, Orhan
dc.contributor.authorYildizgoren, Mustafa Turgut
dc.contributor.authorIlgen, Ufuk
dc.contributor.authorAtes, Askin
dc.contributor.authorKinikli, Gulay
dc.contributor.authorTurgay, Murat
dc.contributor.authorErten, Sukran
dc.date.accessioned2024-09-18T19:54:18Z
dc.date.available2024-09-18T19:54:18Z
dc.date.issued2017
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractObjective: To investigate the effect of anti-interleukin-1 (anti-IL-1) treatment on the frequency and severity of attacks and other disease-related clinical parameters and to evaluate the adverse effects associated with anti-IL-1 treatment in 26 patients with refractory familial mediterranean fever (FMF).Methods: The study included 26 FMF patients followed up in our centre using colchicine for 4 months to 30 years. The treatment was switched to anti-IL-1 treatment for various reasons; 20 cases were resistant to colchicine, 8 were intolerant to colchicine, and 3 had prolonged arthritis under colchicine. Clinical response was monitored through the number of attacks, and laboratory inflammation was monitored through erythrocyte sedimentation rate, C-reactive protein, and serum amyloid A concentrations. Colchicine resistance was defined as at least two attacks/month together with C-reactive protein and serum amyloid A levels above the normal range between attacks. The colchicine dose was increased to 2mg/day before they were considered colchicine-resistant.Results: 24 patients used anakinra (100mg/day), and 2 used canakinumab (150mg/month), for -36 months. Sixteen patients with colchicine resistance had no attacks under anti-IL-1 treatment, and 4 had decreased frequency and duration of attacks. Seven of 8 patients intolerant to colchicine used anakinra, and 6 were attack-free under treatment, while 1 using canakinumab had attacks under treatment. One patient with prolonged arthritis used canakinumab but arthritis showed progression and the treatment was changed to IL-6 inhibitor. Three patients had injection site erythema and one had fatigue with anti-IL-1 treatment. Topical steroids with systemic antihistaminics were sufficient for symptom control in two cases, but canakinumab treatment was given due to severe injection site erythema in one case.Conclusion: Anti-IL-1 agents are rational treatment modalities in patients resistant or intolerant to colchicine. Anti-IL-1 agents can control FMF attacks quite effectively and they have a promising role in the treatment of FMF.en_US
dc.identifier.doi10.1080/14397595.2016.1194510
dc.identifier.endpage355en_US
dc.identifier.issn1439-7595
dc.identifier.issn1439-7609
dc.identifier.issue2en_US
dc.identifier.pmid27328763en_US
dc.identifier.scopus2-s2.0-84975517223en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage350en_US
dc.identifier.urihttps://doi.org/10.1080/14397595.2016.1194510
dc.identifier.urihttps://hdl.handle.net/20.500.12483/7636
dc.identifier.volume27en_US
dc.identifier.wosWOS:000395412300024en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofModern Rheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnakinraen_US
dc.subjectCanakinumaben_US
dc.subjectColchicineen_US
dc.subjectFamilial meditarrenean feveren_US
dc.subjectInterleukin-1en_US
dc.titleAnti-interleukin-1 treatment in 26 patients with refractory familial mediterranean feveren_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
7636.pdf
Boyut:
257.37 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu